| Nom du produit | Noopept |
| Other Names | GVS-111; N-Phenylacetyl-L-prolylglycine ethyl ester |
| Numéro CAS | 157115-85-0 |
| Formule moléculaire | C₁₇H₂₂N₂O₄ |
| Poids moléculaire | 334.37 g/mol |
| Apparence | Poudre cristalline blanche à blanc cassé |
| Essai (HPLC) | ≥ 99.0% |
| Point de fusion | 95–98°C |
| Perte au séchage | ≤ 0.5% |
| Residue on Ignition | ≤ 0.1% |
| Métaux lourds | ≤ 10 ppm |
Besoin d'aide ? Contacter notre équipe
Noopept (developmental code GVS-111) is a dipeptide nootropic compound developed in Russia in the 1990s as a novel cognitive enhancer with neuroprotective properties. Structurally, it is a cycloprolyl-glycine derivative that shares some pharmacological similarities with racetams (particularly piracetam), but with significantly higher potency—estimated to be approximately 1,000 times more potent than piracetam.
Key : Unlike most nootropics that require weeks to show effects, Noopept has demonstrated rapid onset in research models. It exhibits both cognitive-enhancing and neuroprotective properties, including protection against oxidative stress, excitotoxicity, and ischemia-reperfusion injury. Noopept also increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus.
Noopept exerts its effects through multiple pathways, distinguishing it from classic racetams:
| Pathway | Mechanism | Research Finding |
|---|---|---|
| BDNF/NGF upregulation | Increases brain-derived neurotrophic factor and nerve growth factor in hippocampus | Supports synaptic plasticity, neurogenesis |
| AMPA/kainate receptor modulation | Positive allosteric modulation (similar to racetams) | Enhances glutamatergic transmission |
| Neuroprotection | Reduces oxidative stress, inhibits lipid peroxidation, protects against excitotoxicity | Preclinical models of ischemia, traumatic brain injury |
| Cholinergic system | May enhance acetylcholine release (indirect) | Memory and learning support |
| Anti-inflammatory | Reduces neuroinflammation (preclinical) | Neuroprotection |
Noopept has been shown to protect against neurodegeneration in animal models of Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. It reduces amyloid-β toxicity and may have disease-modifying potential (preclinical only).
LyvBio Co. is a GMP-certified supplier of high-purity Noopept (GVS-111) for research and development applications.
Capacités d'approvisionnement :
Assay (HPLC): ≥99.0%
Forme : Crystalline powder
Capacité mensuelle : 20+ kg
Quantités en vrac : 1g – 10kg
Délai d'exécution : 3-5 jours (échantillons), 10-15 jours (vrac)
Documentation : COA, MSDS, HNMR , HPLC chromatogram, stability data
L'assurance qualité :
HPLC purity with UV detection
Residual solvents tested (meets USP <467>)
Heavy metals tested (ICP-MS)
Structural confirmation (NMR upon request)
📧 Demandes de renseignements : info@lyvbio.com
| Parameter | Specification | Test Method |
|---|---|---|
| Essai (HPLC) | ≥ 99.0% | HPLC-UV (210 nm) |
| Apparence | Poudre cristalline blanche à blanc cassé | Visual |
| Identification | HPLC retention time, NMR (upon request) | HPLC / NMR |
| Point de fusion | 95–98°C | USP <741> |
| Perte au séchage | ≤ 0.5% | USP <731> |
| Residue on Ignition | ≤ 0.1% | USP <281> |
| Métaux lourds | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| Related Substances | Single impurity ≤ 0.5%; Total ≤ 1.0% | HPLC-UV |
| Residual Solvents | Meet USP <467> | GC |
| Particle Size | 95% through 80 mesh | Sieve Analysis |
Q: Is Noopept the same as Piracetam?
A: No. Noopept is a dipeptide derivative with different chemical structure, significantly higher potency (~1,000x), and distinct mechanisms (including BDNF/NGF upregulation). It is not a racetam, though it shares some pharmacological similarities.
Q: Is Noopept FDA-approved?
A: No. Noopept is not FDA-approved for medical use in the United States. It is available as a research chemical for laboratory use only. It has been used as a prescription medication in Russia.
Q: What is the difference between Noopept and other nootropics?
A: Noopept is unique in its ability to upregulate BDNF and NGF in the hippocampus—a property not shared by classic racetams. It is also significantly more potent (microgram vs. milligram dosing).
Q: What is the primary active metabolite of Noopept?
A: Cycloprolylglycine (CPG). Noopept is rapidly metabolized to CPG, which is believed to contribute significantly to its pharmacological effects.
Q: Does Noopept have neuroprotective properties?
A: Yes. Preclinical studies have demonstrated neuroprotective effects in models of stroke, traumatic brain injury, excitotoxicity, and neurodegeneration (Alzheimer’s, Parkinson’s models).
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing and neuroprotective effects at 0.1–1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Noopept?
A: Limited human studies have been conducted in Russia, where Noopept is approved as a prescription nootropic.
Demandes de renseignements : info@lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese